Individuals' experiences in genetic counseling and predictive testing for familial amyotrophic lateral sclerosis

被引:2
|
作者
Steigerwald, Connolly G. [1 ,2 ]
Bertolini, Carina [1 ]
McElhiney, Martin [3 ,4 ]
Bergner, Amanda L. [1 ,5 ]
Harms, Matthew B. [6 ]
Harrington, Elizabeth A. [1 ,6 ]
机构
[1] Columbia Univ, Vagelos Coll Phys & Surg, Genet Counseling Grad Program, New York, NY USA
[2] NYU Grossman Sch Med, Dept Neurol, Div Neurogenet, New York, NY 10016 USA
[3] Columbia Univ, Vagelos Coll Phys & Surg, Dept Psychiat, New York, NY USA
[4] New York State Psychiat Inst & Hosp, New York, NY USA
[5] Columbia Univ, Vagelos Coll Phys & Surg, Dept Genet & Dev, New York, NY USA
[6] Columbia Univ, Vagelos Coll Phys & Surg, Dept Neurol, New York, NY USA
关键词
decision making; genetic counseling; lived experience; predictive genetic testing; psychosocial; HUNTINGTONS-DISEASE; PSYCHOLOGICAL IMPACT; MUTATIONS; PENETRANCE; PROGNOSIS; DECISION; UPDATE; ALS;
D O I
10.1002/jgc4.1890
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
As clinical genetic testing in the amyotrophic lateral sclerosis (ALS) diagnostic setting increases, the identification of at-risk family members has also expanded. No practice guidelines specifically for predictive genetic testing exist, and few studies about the psychological impacts of testing in this subgroup have occurred, limiting the ability to tailor recommendations and counseling in this community. We surveyed asymptomatic individuals at risk for inheriting an ALS-associated gene mutation. The 80-question survey was designed using a combination of validated measures (General Anxiety Disorder; FACToR; Decision Regret Scale) and original items. Ninety participants completed the survey, including those who completed predictive genetic testing (N = 42) and those who did not (N = 48). Gene positive individuals experienced greater negativity, uncertainty, and overall psychological impairment (p = 0.002; p < 0.001; p = 0.001). Individuals who had not undergone testing reported thinking about their risk multiple times per day and experiencing more decisional regret than those who tested (p = 0.006). In terms of decision-making, being prepared for potential clinical drug trials was a more important potential benefit among those who underwent testing (p = 0.026). Participants valuing preparedness for clinical drug trials supports the concept that genetic testing for ALS will increase as research in gene-targeted therapeutics progresses. This study describes factors relevant to the genetic testing decision-making process and adaptation to results from the perspective of at-risk individuals, which can ultimately guide genetic counseling practice in this population.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] The unfolded protein response in familial amyotrophic lateral sclerosis
    Wang, Lijun
    Popko, Brian
    Roos, Raymond P.
    HUMAN MOLECULAR GENETICS, 2011, 20 (05) : 1008 - 1015
  • [42] Primary lateral sclerosis may occur within familial amyotrophic lateral sclerosis pedigrees
    Praline, Julien
    Guennoc, Anne-Marie
    Vourc'h, Patrick
    De Toffol, Bertrand
    Corcia, Philippe
    AMYOTROPHIC LATERAL SCLEROSIS, 2010, 11 (1-2): : 154 - 156
  • [43] Neurophysiological Testing in the Diagnosis of Amyotrophic Lateral Sclerosis
    Burke, David
    NEUROLOGICAL SCIENCES AND NEUROPHYSIOLOGY, 2022, 39 (01): : 1 - 7
  • [44] Late AAC Assessment for Individuals with Amyotrophic Lateral Sclerosis
    Nordness, Amy S.
    Ball, Laura J.
    Fager, Susan
    Beukelman, David R.
    Pattee, Gary L.
    JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY, 2010, 18 (01) : 48 - U1
  • [45] Profiles of Dysarthria and Dysphagia in Individuals With Amyotrophic Lateral Sclerosis
    Donohue, Cara
    Gray, Lauren Tabor
    Anderson, Amber
    DiBiase, Lauren
    Wymer, James P.
    Plowman, Emily K.
    JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH, 2023, 66 (01): : 154 - 162
  • [46] Current insights in the molecular genetic pathogenesis of amyotrophic lateral sclerosis
    Zhou, Wan
    Xu, Renshi
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [47] ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling
    Gellera, Cinzia
    Ticozzi, Nicola
    Pensato, Viviana
    Nanetti, Lorenzo
    Castucci, Alessia
    Castellotti, Barbara
    Lauria, Giuseppe
    Taroni, Franco
    Silani, Vincenzo
    Mariotti, Caterina
    NEUROBIOLOGY OF AGING, 2012, 33 (08) : e15 - e21
  • [48] Comprehensive Genetic Analysis of a Hungarian Amyotrophic Lateral Sclerosis Cohort
    Tripolszki, Kornelia
    Gampawar, Piyush
    Schmidt, Helena
    Nagy, Zsofia F.
    Nagy, Dora
    Klivenyi, Peter
    Engelhardt, Jozsef, I
    Szell, Marta
    FRONTIERS IN GENETICS, 2019, 10
  • [49] Value of systematic genetic screening of patients with amyotrophic lateral sclerosis
    Shepheard, Stephanie R.
    Parker, Matthew D.
    Cooper-Knock, Johnathan
    Verber, Nick S.
    Tuddenham, Lee
    Heath, Paul
    Beauchamp, Nick
    Place, Elsie
    Sollars, Elizabeth S. A.
    Turner, Martin R.
    Malaspina, Andrea
    Fratta, Pietro
    Hewamadduma, Channa
    Jenkins, Thomas M.
    McDermott, Christopher J.
    Wang, Dennis
    Kirby, Janine
    Shaw, Pamela J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (05) : 510 - 518
  • [50] Rate of speech decline in individuals with amyotrophic lateral sclerosis
    Eshghi, Marziye
    Yunusova, Yana
    Connaghan, Kathryn P.
    Perry, Bridget J.
    Maffei, Marc F.
    Berry, James D.
    Zinman, Lorne
    Kalra, Sanjay
    Korngut, Lawrence
    Genge, Angela
    Dionne, Annie
    Green, Jordan R.
    SCIENTIFIC REPORTS, 2022, 12 (01)